If you have been reading about thymosin beta-4 fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Troika attempted to equalize the disciplines, keeping the effect intact and normalizing the cost, so a first-level power requires one blood point, a second-level two points, and so on. To balance the clans, the aristocratic Ventrue were only allowed to feed on noble blood, though this was changed to allow them to feed on lower-class humans, receiving less blood. During character creation, the game had an optional character biography with unique positive and negative characteristics (increasing one ability while limiting another). This was removed from the released game; Activision felt there was insufficient test time, and removing it was a more stable option. The team's previous experience was with turn-based combat games, and it struggled to develop a real-time combat system affected by customizable attributes and abilities that provided feedback to the player on how those statistics affected the battle. It initially found that by adhering too closely to the White Wolf source material rules for guns, where the effectiveness of a shot is determined in a contest between the player's skill and the opponent's defense, the firearms seemed broken; the player would not hit where they aimed. Troika found it difficult to mesh the available factors in a real-time setting. Melee combat had to deal with various melee weapons and animations and adjust for melee-on-melee and melee-on-ranged combat. Troika used first-person perspective to immerse the player in the setting, interacting face-to-face with the characters and seeing their facial reactions to the player.
Insulin efsitora alfa, sold under the brand name Onswik, is an antidiabetic medication used for the treatment of type 2 diabetes. It is a long-acting insulin analog developed by Eli Lilly. Insulin efsitora alfa was authorized for medical use in the European Union in August 2026, and approved for medical use in the United States in September 2026.
=== Amino acid metabolism === Clostridium scindens also has the genetic potential to perform Stickland fermentation, or the generation of ATP through the fermentation of amino acids. C. scindens pairs amino acid fermentation with bile acid metabolism by using amino acids as electron donors and primary bile acids as acceptors. The presence of glycine and proline reductase enzymes in the Clostridium scindens ATCC35704 genome indicates that glycine and proline may be commonly fermented amino acids by this organism.
Ciskei – general information African Studies Quarterly South African history site WHKMLA site Creation of tribalism in Ciskei Ciskei International Airways CV-990 Video showing a GIS time animation of the assembly of Ciskei
Finally, Marshall and coworkers found that P-selectin:PSGL-1 bonds exhibited increasing bond lifetime as step loads were applied between 0 and ~10 pN for monomeric interaction but 1 and ~20 pN for dimeric interaction, exhibiting catch bond behavior; after reaching maximum values, which were ~0.6 and 1.2 seconds for monomeric and dimeric interaction, respectively, the bond lifetime fell rapidly at higher loads, displaying slip bond behavior ("catch-slip" bonds). These data were collected using an atomic force microscope and a flow chamber, and have subsequently been duplicated using a biomembrane force probe. These finding prompted the discoveries of other important catch bonds in the 2000s, including those between L-selectin and PSGL-1 or endoglycan, FimH and mannose, myosin and actin, platelet glycoprotein Ib and von Willebrand factor, and integrin alpha 5 beta 1 and fibronectin. Emphasizing their importance and general acceptance, in the three years following their discovery there were at least 24 articles published on catch bonds. More catch bonds were discovered in the 2010s, including E-selectin with carbohydrate ligands, G-actin with G-actin or F-actin, cadherin-catenin complex with actin, vinculin with F-actin, microtubule with kinetochore particle, integrin alpha L beta 2 and intercellular adhesion molecule 1 (ICAM-1), integrin alpha 4 beta 1 with vascular adhesion molecule 1, integrin alpha M beta 2 with ICAM-1, integrin alpha V beta 3 with fibronectin, and integrin alpha IIb beta 3 with fibronectin or fibrinogen.
Sources: en.wikipedia.org
== Research interests == Among his many research interests, Hunt investigates how the immune system uses peptides to kill diseased cells, and how modifications to chromatin-associated proteins called histones create a "Code" that may be involved in many gene regulation events.
Half-Life is a series of first-person shooter games created by Valve. The games combine shooting combat, puzzles and storytelling, and are played entirely from the first-person perspective. The original Half-Life, Valve's first product, was released in 1998 for Windows. Players control silent protagonist Gordon Freeman, a scientist working at the Black Mesa Research Facility who must survive an alien invasion caused by the facility. The use of innovative scripted sequences instead of cutscenes was influential on the first-person shooter genre, and the game inspired numerous community-developed mods, leading to the release of the multiplayer games Counter-Strike and Day of Defeat. Half-Life was followed by the expansions Opposing Force (1999), Blue Shift (2001) and Decay (2001), developed by Gearbox Software. In 2004, Valve released Half-Life 2, developed using their game engine Source. It features a more dystopian setting, stronger focus on characters and physics-based gameplay. Set twenty years after Half-Life, players control Freeman in joining a resistance to liberate humanity from an alien force known as the Combine. It was followed by the episodic sequels Episode One (2006) and Episode Two (2007). Also set in the same universe as Half-Life is the Portal series; the first game was released in 2007 followed by a sequel in 2011. Both games focus on first-person puzzle-platform gameplay using wormholes created by a portal gun.
===== Australia ===== Epilim Crushable Tablets Sanofi Epilim Sugar Free Liquid Sanofi Epilim Syrup Sanofi Epilim Tablets Sanofi Sodium Valproate Sandoz Tablets Sanofi Valpro Tablets Alphapharm Valproate Winthrop Tablets Sanofi Valprease tablets Sigma
In 1969, the dictator Francisco Franco designated Juan Carlos de Borbón as his successor "by title of king" with the title of Prince of Spain, by virtue of the Law of Succession to the Headship of the State of 1947. After Franco's death on November 20, 1975, the Regency Council assumed interim rule. Two days later, Juan Carlos I was proclaimed king before the Francoist Cortes. He delivered a speech in which he avoided referencing Franco's triumph in the Spanish Civil War and in which, after expressing his "respect and gratitude" to Franco, he stated that he intended to reach "an effective consensus of national concord". In this way, he made it clear that he did not support the pure "immobilist continuism" advocated by the búnker ─ which defended the perpetuation of Francoism under the monarchy established by Franco, following the model established in the Organic Law of the State of 1967─ but with a message to the Army to face the future with "serene tranquility" that hinted that the reform would be made from the regime's own institutions. The most enthusiastic round of applause from the Cortes, however, was not for the new king but for Franco's family present at the ceremony. The anti-Franco opposition received the king's speech with coldness. The ratification of Carlos Arias Navarro as President of the Government caused enormous disappointment, barely mitigated by the appointment of Torcuato Fernández Miranda, former tutor to the prince, as the new President of the Cortes and of the Council of the Realm, key institutions in the framework left by the Franco dictatorship.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.